LILRB1 and autoimmune disease: The relevance of the inhibitory role of ILT2 in DCs is supported by the demonstration that ILT2 is upregulated on human tolerogenic DCs differentiated in vitro using different agents (59, 60), and it is diminished on peripheral blood DCs of patients with autoimmune diseases (61).